PNH

18 registered clinical trials studyying PNH — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: NCT07413250	Alexion Pharmaceuticals, Inc.	—
Active Not Recruiting	Long-term Safety of Danicopan: IPIG Registry-based Cohort Study NCT07413679	Alexion Pharmaceuticals, Inc.	—
Recruiting	Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Hav NCT06449001	Alexion Pharmaceuticals, Inc.	Phase 3
Completed	A Phase III Study to Evaluate the Efficacy and Safety of HSK39297 in Patients With Paroxysmal Nocturnal Hemogl NCT06799546	Haisco Pharmaceutical Group Co., Ltd.	Phase 3
Completed	Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adults Part NCT06578949	Alexion Pharmaceuticals, Inc.	Phase 3
Unknown	A Study on the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of CAN106 in Subjects Wit NCT05539248	CARE Pharma Shanghai Ltd.	Phase 1 / Phase 2
Terminated	Complement Regulation to Undo Systemic Harm in Preeclampsia NCT04725812	Cedars-Sinai Medical Center	Phase 2
Completed	Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN1 NCT05095168	CARE Pharma Shanghai Ltd.	Phase 1
Terminated	A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT04702568	BioCryst Pharmaceuticals	Phase 2
Completed	A Retrospective Non-Interventional Study to Evaluate the Impact of Eculizumab in Korean PNH Patients NCT05337683	Handok Inc.	—
Active Not Recruiting	Pegcetacoplan Long Term Safety and Efficacy Extension Study NCT03531255	Apellis Pharmaceuticals, Inc.	Phase 3
Completed	A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetac NCT03593200	Apellis Pharmaceuticals, Inc.	Phase 2
Completed	Retrospective Chart Review Screening Algorithm to Assess the Prevalence of PNH-clones NCT05884060	AZ Delta	—
Completed	Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal NCT02605993	Alexion Pharmaceuticals, Inc.	Phase 2
Completed	Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) NCT02598583	Alexion Pharmaceuticals, Inc.	Phase 1 / Phase 2
Completed	Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH NCT03460301	Handok Inc.	—
Completed	Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study NCT01412047	Alexion Pharmaceuticals, Inc.	—
Available	Danicopan Early Access Program NCT05982938	Alexion Pharmaceuticals, Inc.	—